Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Capital Expenditures of $86000.0 for Q1 2026, down 70.45% year-over-year from $291000.0 in Q1 2025, and down 49.11% quarter-over-quarter from $169000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Capital Expenditures for 4 consecutive years, with $86000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 70.45% year-over-year to $86000.0; the TTM figure through Mar 2026 stood at $411000.0 (down 74.69% YoY), while the FY2025 annual figure was $616000.0, down 74.39% from the prior year.
- Capital Expenditures eased to $86000.0 in Q1 2026 per RAPP's latest filing, from $169000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.4 million in Q4 2023 and bottomed at $22000.0 in Q2 2025.
- Historically, Capital Expenditures has averaged $417818.2 across 4 years, with a median of $169000.0 in 2025.
- Annual changes were most pronounced in 2024 — Capital Expenditures surged 169.23% — and 2025, when it slumped 97.72%.
- Rapport Therapeutics' Capital Expenditures stood at $1.4 million in 2023, then plunged by 84.27% to $226000.0 in 2024, then slipped by 25.22% to $169000.0 in 2025, then tumbled by 49.11% to $86000.0 in 2026.
- Business Quant data shows RAPP's Capital Expenditures at $86000.0 in Q1 2026, $169000.0 in Q4 2025, and $134000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 86,000.00 |
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 967,000.00 |
| Jun 30, 2024 | 967,000.00 |
| Mar 31, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.07 Mn |